|
Oct 10
|
Mainz Biomed Secures Additional $1.5M Funding
|
|
Oct 8
|
Mainz Biomed Reports Increased Demand for Enhanced ColoAlert, Existing Partners to Transition to New Version
|
|
Sep 20
|
Pfizer Advances On Its Cancer Journey
|
|
Jul 30
|
Pfizer Records First Sales Growth In Its Post-Covid Era And It Owes It To Cancer
|
|
Jul 25
|
Mainz Biomed Launches Enhanced ColoAlert with Cutting-Edge Features to Optimize Screening Efficiency and User Convenience
|
|
Jul 10
|
Mainz Biomed seeks FDA breakthrough device status for colorectal cancer test
|
|
Mar 19
|
Mainz Biomed Organizes HALLO DOC! Event to Highlight Innovations in Colorectal Cancer Treatment
|
|
Mar 18
|
Mainz Biomed: Webinar on Early Detection of Colorectal Cancer - Exploring New Laboratory Diagnostic Options
|
|
Feb 21
|
Mainz Biomed Establishes Strategic Partnership with TomaLab to Expand Availability of ColoAlert® in Italy
|
|
Jan 11
|
Mainz Biomed and TestDNA Drive CRC Innovation at the 10th Gdańsk Gastroenterology Symposium
|
|
Jan 9
|
2024 Marks a New Era Of Pharmaceutical Innovation
|
|
Jan 9
|
Mainz Biomed Provides Year-End Corporate Review 2023
|
|
Dec 29
|
2023 Will Go Down As The Year Pharma Showed Its Determination To Beat Cancer
|
|
Dec 19
|
Mainz Biomed and Bantleon Partner to Elevate Corporate Health with Second Phase of CRC Screening Program for Employees
|
|
Dec 12
|
Mainz Biomed Showcases ColoAlert® at Two Prominent Gastroenterology Conferences in Poland
|
|
Dec 5
|
While Pfizer Faced A Setback, Altimmune, Roche And Mainz Biomed Advanced in The Battle Against Obesity And Colorectal Cancer
|
|
Dec 5
|
Mainz Biomed Reports Positive Topline Results from U.S. eAArly DETECT Study Evaluating Novel mRNA Biomarkers
|
|
Nov 29
|
Mainz Biomed’s Presentation at the 35th Annual Piper Sandler Healthcare Conference to be Made Available via Webcast
|
|
Aug 29
|
Mainz Biomed to Present at the H.C. Wainwright Global Investment Conference
|
|
Jun 29
|
Mainz Biomed Secures up to $50M in New Funding
|